pksi-527 has been researched along with Thrombosis* in 2 studies
2 other study(ies) available for pksi-527 and Thrombosis
Article | Year |
---|---|
Synergistic antithrombotic effect of a combination of NO donor and plasma kallikrein inhibitor.
The aim of the present study was to investigate the effect of a NO donor (GSNO) and a plasma kallikrein inhibitor (PKSI-527) alone and in combination on global haemostatic status. A new in vitro test was employed which allows the measurement of both platelet function and spontaneous thrombolysis. Sixteen healthy young and 18 elderly volunteers were enrolled in this study. When GSNO (1 mM) or PKSI-527 (20 microM) was added to native human blood, platelet reactivity was significantly inhibited in both age groups. The combination of GSNO and PKSI-527 had additive inhibitory effect on platelets. Addition of either GSNO or PKSI-527 to blood samples did not significantly affect spontaneous thrombolysis, while added together, spontaneous thrombolysis was significantly enhanced. The thrombolysis enhancing effect was more prominent in elderly subjects. Our present findings suggest that the combination of NO donor and plasma kallikrein inhibitor may have clinical antithrombotic potential. Topics: Adult; Aged; Blood Platelets; Drug Synergism; Female; Fibrinolytic Agents; Humans; In Vitro Techniques; Kallikreins; Male; Middle Aged; Nitric Oxide Donors; Phenylalanine; S-Nitrosoglutathione; Thrombosis; Tranexamic Acid | 2005 |
Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
We have previously confirmed, using a rat mesenteric arteriole thrombolysis model, that thrombin inhibition induces endogenous thrombolysis in vivo. In addition, we have shown that thrombin-activatable fibrinolysis inhibitor (TAFI) plays a role in the down regulation of endogenous thrombolysis. However, the mechanism of endogenous thrombolysis or spontaneous plasmin generation in vivo remains unclear. It has been shown in an in vitro system that plasma kallikrein activates pro-urokinase (pro uPA) and/or plasminogen, resulting in plasmin generation. These findings suggest that spontaneous fibrinolysis might be mediated by tPA and plasma kallikrein-dependent uPA. The aim of the present study was to examine whether these mechanisms play a dominant role in endogenous thrombolysis in vivo, using our rat mesenteric arterial thrombolysis model. Argatroban infusion enhanced endogenous thrombolysis. PKSI-527, anti uPA and anti tPA IgGs suppressed argatroban-induced thrombolysis. Also, the antibody IgG preparations suppressed endogenous thrombolysis in the absence of argatroban. In the presence of PKSI-527, anti tPA IgG was more effective than anti uPA IgG in suppressing argatroban-induced thrombolysis. The results suggested that both tPA and plasma kallikrein-mediated uPA activation and tPA release contribute to endogenous fibrinolytic or thrombolytic mechanisms. Topics: Animals; Antibodies; Arginine; Drug Antagonism; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Kallikreins; Male; Mesenteric Arteries; Phenylalanine; Pipecolic Acids; Plasma Kallikrein; Rats; Rats, Wistar; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator; Tranexamic Acid; Urokinase-Type Plasminogen Activator | 2003 |